India: Kemwell Biopharma invests $13.7m in Manipal Group’s Stempeutics Research

India: Kemwell Biopharma invests $13.7m in Manipal Group’s Stempeutics Research

Photo: Mint

Stempeutics Research, backed by Ranjan Pai’s Manipal Education and Medical Group (MEMG) has signed an agreement to raise ₹95 crore from Bengaluru-based Kemwell Biopharma, for global commercialization of its stem cell product Stempeucel.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter